An early economic evaluation of active surveillance for low-risk ductal carcinoma in situ

Danalyn Byng; Michael Schaapveld; Esther H. Lips; Frederieke H. van Duijnhoven; Jelle Wesseling; Wim H. van Harten; Valesca P. Retèl

doi:10.1080/14796694.2024.2421152

An early economic evaluation of active surveillance for low-risk ductal carcinoma in situ

Danalyn Byng
, Michael Schaapveld
, Esther H. Lips
, Frederieke H. van Duijnhoven
, Jelle Wesseling
, Wim H. van Harten
, Valesca P. Retèl^*

^*Corresponding author for this work

Health Technology Assessment (HTA)

Antoni van Leeuwenhoek Hospital
Erasmus University Rotterdam
Leiden University

Research output: Contribution to journal › Article › Academic › peer-review

1 Citation (Scopus)

48 Downloads (Pure)

Abstract

Aim: Perform early economic evaluation comparing active surveillance (AS) to surgery for women with low-risk ductal carcinoma in situ, a precursor of invasive breast cancer. Materials & methods: A 10-year incremental costs (€) and quality-adjusted life years (QALYs) were compared between a simulated cohort of women undergoing breast conserving surgery ± radiotherapy, and a cohort with a low-risk subgroup undergoing AS using a semi-Markov model. Scenario and headroom analyses evaluated a better-performing biomarker to select low-risk women for AS. Results: AS resulted in lower costs and survival, but higher QALYs (±0.40). Scenario analyses maintained survival outcomes and maximized QALYs. Conclusion: AS for low-risk ductal carcinoma in situ is cost-effective, but a better-performing biomarker to select low-risk women can maximize quality-adjusted outcomes.

Original language	English
Pages (from-to)	3451-3462
Number of pages	12
Journal	Future Oncology
Volume	20
Issue number	40
Early online date	16 Dec 2024
DOIs	https://doi.org/10.1080/14796694.2024.2421152
Publication status	Published - 2024

Bibliographical note

Publisher Copyright:
© 2024 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group.

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Access to Document

10.1080/14796694.2024.2421152Licence: CC BY

An early economic evaluation of active surveillance for low-risk ductal carcinoma in situFinal published version, 1.9 MBLicence: CC BY

Cite this

@article{1e3e3811902a4b8398bd8e72ea4b7642,

title = "An early economic evaluation of active surveillance for low-risk ductal carcinoma in situ",

abstract = "Aim: Perform early economic evaluation comparing active surveillance (AS) to surgery for women with low-risk ductal carcinoma in situ, a precursor of invasive breast cancer. Materials \& methods: A 10-year incremental costs (€) and quality-adjusted life years (QALYs) were compared between a simulated cohort of women undergoing breast conserving surgery ± radiotherapy, and a cohort with a low-risk subgroup undergoing AS using a semi-Markov model. Scenario and headroom analyses evaluated a better-performing biomarker to select low-risk women for AS. Results: AS resulted in lower costs and survival, but higher QALYs (±0.40). Scenario analyses maintained survival outcomes and maximized QALYs. Conclusion: AS for low-risk ductal carcinoma in situ is cost-effective, but a better-performing biomarker to select low-risk women can maximize quality-adjusted outcomes.",

author = "Danalyn Byng and Michael Schaapveld and Lips, \{Esther H.\} and \{van Duijnhoven\}, \{Frederieke H.\} and Jelle Wesseling and \{van Harten\}, \{Wim H.\} and Ret{\`e}l, \{Valesca P.\}",

note = "Publisher Copyright: {\textcopyright} 2024 The Author(s). Published by Informa UK Limited, trading as Taylor \& Francis Group.",

year = "2024",

doi = "10.1080/14796694.2024.2421152",

language = "English",

volume = "20",

pages = "3451--3462",

journal = "Future Oncology",

issn = "1479-6694",

publisher = "Taylor \& Francis Ltd (UK)",

number = "40",

}

TY - JOUR

T1 - An early economic evaluation of active surveillance for low-risk ductal carcinoma in situ

AU - Byng, Danalyn

AU - Schaapveld, Michael

AU - Lips, Esther H.

AU - van Duijnhoven, Frederieke H.

AU - Wesseling, Jelle

AU - van Harten, Wim H.

AU - Retèl, Valesca P.

PY - 2024

Y1 - 2024

N2 - Aim: Perform early economic evaluation comparing active surveillance (AS) to surgery for women with low-risk ductal carcinoma in situ, a precursor of invasive breast cancer. Materials & methods: A 10-year incremental costs (€) and quality-adjusted life years (QALYs) were compared between a simulated cohort of women undergoing breast conserving surgery ± radiotherapy, and a cohort with a low-risk subgroup undergoing AS using a semi-Markov model. Scenario and headroom analyses evaluated a better-performing biomarker to select low-risk women for AS. Results: AS resulted in lower costs and survival, but higher QALYs (±0.40). Scenario analyses maintained survival outcomes and maximized QALYs. Conclusion: AS for low-risk ductal carcinoma in situ is cost-effective, but a better-performing biomarker to select low-risk women can maximize quality-adjusted outcomes.

AB - Aim: Perform early economic evaluation comparing active surveillance (AS) to surgery for women with low-risk ductal carcinoma in situ, a precursor of invasive breast cancer. Materials & methods: A 10-year incremental costs (€) and quality-adjusted life years (QALYs) were compared between a simulated cohort of women undergoing breast conserving surgery ± radiotherapy, and a cohort with a low-risk subgroup undergoing AS using a semi-Markov model. Scenario and headroom analyses evaluated a better-performing biomarker to select low-risk women for AS. Results: AS resulted in lower costs and survival, but higher QALYs (±0.40). Scenario analyses maintained survival outcomes and maximized QALYs. Conclusion: AS for low-risk ductal carcinoma in situ is cost-effective, but a better-performing biomarker to select low-risk women can maximize quality-adjusted outcomes.

UR - https://www.scopus.com/pages/publications/85212196336

U2 - 10.1080/14796694.2024.2421152

DO - 10.1080/14796694.2024.2421152

M3 - Article

C2 - 39676693

AN - SCOPUS:85212196336

SN - 1479-6694

VL - 20

SP - 3451

EP - 3462

JO - Future Oncology

JF - Future Oncology

IS - 40

ER -

An early economic evaluation of active surveillance for low-risk ductal carcinoma in situ

Abstract

Bibliographical note

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this